<SEC-DOCUMENT>0001055726-24-000053.txt : 20241114
<SEC-HEADER>0001055726-24-000053.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114160757
ACCESSION NUMBER:		0001055726-24-000053
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241114
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241114
DATE AS OF CHANGE:		20241114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		241462077

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ino-20241114.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3171d0de-669c-4698-8a3a-dc1a7aa79716,g:5bb66b14-731b-41b6-9a0c-052f9423fe35,d:22027dae778e4630828738e99450caab-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20241114</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20241114.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-14</xbrli:startDate><xbrli:endDate>2024-11-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i22027dae778e4630828738e99450caab_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, DC 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 14, 2024</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Inovio Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.800%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-14888</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">660 W. Germantown Pike</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 110</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Plymouth Meeting</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">PA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">19462</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">267</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">440-4200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Former name or former address, if changed since last report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.800%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:2pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 14, 2024, Inovio Pharmaceuticals, Inc. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d) Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93024x8kex991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-93024x8kex991.htm">Press Release, dated November 14, 2024 (filed herewith)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL).</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.935%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 14, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter Kies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter Kies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ino-93024x8kex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i56ffff489a144fd5b6daf92cec4f6c71_36"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="picture3.jpg" src="picture3.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13pt">New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1&#47; 2 trial</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13pt">Continued progress on preparing regulatory submissions for INO-3107</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">All non-device BLA modules on track for completion by end of 2024 </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">BLA submission remains targeted for mid-2025</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PLYMOUTH MEETING, PA &#8211; November 14, 2024 &#8211; INOVIO (NASDAQ&#58; INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;We continue to be focused on advancing INO-3107 and delivering a non-surgical option to RRP patients. Toward this goal, we expect to have all non-device modules for our BLA completed by year end, while in parallel we continue to implement the plan to resolve the previously announced manufacturing issue with the single-use array component of the device. With this progress, we continue to target the submission of our BLA in mid-2025,&#8221; said Dr. Jacqueline Shea, INOVIO&#8217;s President and Chief Executive Officer. &#8220;Our development of INO-3107 is supported by a growing body of research that collectively points to INO-3107&#8217;s potential to be an important therapeutic option for all RRP patients regardless of the severity of their disease. We recently presented new immunology data highlighting the ability of INO-3107 to induce new populations of T cells that travel to the airway tissue and papilloma and correspond with clinical benefit. We&#8217;ve also presented our full safety and efficacy data, demonstrating that INO-3107 was shown to be well tolerated and have clinical benefit in the Phase 1&#47;2 trial. Additionally, by the end of year, we anticipate announcing long-term clinical durability data. We continue to believe INO-3107 has the potential to become the preferred choice for the broadest number of RRP patients, healthcare providers and payors, if approved.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Recent Business Highlights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lead Candidate, INO-3107 &#8211; Recurrent Respiratory Papillomatosis</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO&#8217;s primary focus is driving toward the regulatory approval and commercialization of its lead product candidate, INO-3107. Recent progress includes advancing preparations for submitting the BLA, targeted for mid-2025, and announcing the following new data.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">New Immunology Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; INOVIO presented additional immunology data demonstrating the ability of INO-3107 to induce antigen-specific T cell responses against HPV-6 and HPV-11 and drive recruitment of those T cells into airway tissues and papilloma of RRP patients, which could potentially slow or eliminate papilloma regrowth. These data were presented at the American Association for Cancer Research (AACR) Special Conference and at the 36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> International Papillomavirus Conference. In totality, this new data showed&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Induction of T cell responses specific to HPV-6 and HPV-11, including cytotoxic CD8+ T cells, which were still present at week 52, indicating an establishment of memory response</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Expansion of clonal T cell populations in peripheral blood, including induction of new clonal T cell populations that travelled to airway or papilloma tissue</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Induction of inflammatory responses in papilloma and airway tissue, including&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Interferon, cytokine and chemokine signaling</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Adaptive and innate immune cell infiltration, with emphasis on T cells</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Cytotoxic signatures of infiltrated T cells in papilloma&#47;airway tissue, providing direct evidence of increased overall T cell infiltration compared to pre-treatment</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">T cell infiltration in airway tissues of clinical responders were predominantly new T cell clonal populations not detectable prior to INO-3107 treatment</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Clinical activity not impacted by immunosuppressive papilloma microenvironment</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Full Safety and Efficacy Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; INOVIO presented its full safety and efficacy data set for the Phase 1&#47;2 trial in which INO-3107 was shown to be well tolerated and have clinical benefit. Of the 32 patients in the trial, 26 patients, or 81%, experienced a decrease in the number of surgical interventions in the year after treatment when compared to the year before treatment. These data were presented at both the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Society of Vaccines Conference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fall Voice Conference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the trial, the overall clinical response (OCR) was 81%, with 26 of the 32 enrolled patients experiencing a decrease in the number of surgical interventions in the year after INO-3107 administration compared to the prior year, including 28% (9&#47;32) that required no surgical intervention (i.e., complete response, or CR) during or after the dosing window. Further, 44% (14&#47;32) of patients had a partial response (PR), measured by a reduction of at least 50%, but less than 100%, in the number of surgeries when compared to the prior year. The overall response rate (ORR) of patients (CR+PR) was therefore 72% (23&#47;32). Other key data points presented include&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">INO-3107 was shown to be well tolerated and have clinical benefit</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">41% (13&#47;32) of patients reported a treatment-related Adverse Event (AE)</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">No treatment-related AEs greater than Grade 2 severity were reported</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Most frequent treatment-related AE&#8217;s reported were injection site pain (31%) and fatigue (9%)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Modified Derkay-Pransky severity scores improved from baseline to the end of 52-week trial</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INO-3107 induced durable cellular responses and generated T cells against HPV-6 and HPV-11</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Pipeline Updates</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">INOVIO continued to advance plans for a Phase 3 trial of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-3112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as a potential treatment for HPV-related oropharyngeal squamous cell carcinoma also known as throat cancer, through ongoing conversations with regulators in the European Union. This trial is anticipated to be conducted in North America and Europe. Previously, the FDA had indicated alignment with the proposed trial design, which was developed in conjunction with a trial steering committee.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">INOVIO continued to advance its plans for a Phase 2 trial of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-4201</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as a heterologous boost to the FDA licensed Ebola vaccine, Ervebo&#174;. A meeting is scheduled with the FDA in the fourth quarter of 2024 to discuss the proposed Phase 2 trial design.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Patients continue to be dosed in the GBM-001 trial with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-5401</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Regeneron and Inovio have discussed that an appropriate next step would be a controlled Phase 2 trial.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Third Quarter 2024 Financial Results </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Cash, Cash Equivalents and Short-term Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; As of September 30, 2024, cash, cash equivalents and short-term investments were $84.8 million compared to $145.3 million as of December 31, 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Research and Development (R&#38;D) Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">R&#38;D expenses for the three months ended September 30, 2024, were $18.7 million compared to $15.5 million for the same period in 2023. The increase in R&#38;D expenses was primarily the result of overall higher drug manufacturing costs and higher engineering professional and outside services related to device development, offset by lower employee and consultant compensation, including non-cash stock-based compensation, among other variances. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">General and Administrative (G&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> G&#38;A expenses were $8.6 million for the three months ended September 30, 2024 compared to $9.9 million for the same period in 2023. The decrease in G&#38;A </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expenses was primarily related to a decrease in employee compensation, including non-cash employee and consultant stock-based compensation, and a decrease in legal expenses, among other variances. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Total Operating Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total operating expenses were $27.3 million for the three months ended September 30, 2024, compared to $35.9 million for the same period in 2023. During the three months ended September 30, 2023, the company recognized a non-cash goodwill impairment charge of $10.5 million.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Net Loss&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Net loss for the three months ended September 30, 2024 was $25.2 million, or $0.89 per basic and diluted share, compared to net loss of $33.9 million, or $1.52 per basic and diluted share, for the three months ended September 30, 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Shares Outstanding&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> As of September 30, 2024, INOVIO had 26.1 million common shares outstanding, 2.1 million pre-funded warrants outstanding, and 29.9 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding pre-funded warrants, options, restricted stock units and convertible preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO&#8217;s balance sheet and statement of operations are provided below. Additional information is included in INOVIO&#8217;s quarterly report on Form 10-Q for the quarter ended September 30, 2024, which can be accessed at&#58; </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">http&#58;&#47;&#47;ir.inovio.com&#47;financials&#47;default.aspx</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Cash Guidance</font></div><div><font><br></font></div><div style="text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO estimates its cash runway to extend into the third quarter of 2025. This projection includes an operational net cash burn estimate of approximately $24 million for the fourth quarter of 2024. These cash runway projections do not include any further capital-raising activities that INOVIO may undertake.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call &#47; Webcast Information</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO's management will host a live conference call and webcast with slides at 4&#58;30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">http&#58;&#47;&#47;ir.inovio.com&#47;events-and-presentations&#47;default.aspx</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About INOVIO's DNA Medicines Platform</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO&#8217;s DNA medicines platform has two innovative components&#58; precisely designed DNA plasmids, delivered by INOVIO&#8217;s proprietary investigational medical device, CELLECTRA&#174;. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. INOVIO&#8217;s proprietary CELLECTRA&#174; delivery devices are designed to optimally deliver its DNA medicines to the body&#8217;s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About INOVIO</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO&#8217;s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.inovio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Media&#58; Jennie Willson (267) 429-8567 </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">jennie.willson&#64;inovio.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investors&#58; Thomas Hong (267) 440-4298 </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">thomas.hong&#64;inovio.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines and our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, the planned submission of a BLA in mid-2025, expectations regarding INO-3107&#8217;s potential to be an important therapeutic option for RRP patients and the preferred choice of RRP patients, healthcare providers and payors, as well as plans for discussions with regulatory authorities, the planned commercial launch of INO-3107 if regulatory approval is obtained, and expectations with respect to our cash resources into the third quarter of 2025 and expected cash burn for the fourth quarter of 2024. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Inovio Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONSOLIDATED BALANCE SHEETS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,687,480&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,310,862&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,117,288</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130,982,913</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable from affiliated entities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,862,739</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,405,228</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,617,116</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,393,665</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets from affiliated entity</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,432</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,284,623</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,113,100</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,091,562</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,960,986</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in affiliated entity</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,644,226</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,780,287</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,472,848</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,491,735</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">566,415</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605,315</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,059,674&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170,951,423&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,743,191&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,847,744&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses due to affiliated entity</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,834,266</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,070,519</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued clinical trial expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,496,568</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,365,382</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liability</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,425,112</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,406,522</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant funding liability</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,489</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant funding liability from affiliated entity</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,918</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible senior notes</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,770,654</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,499,137</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,570,228</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liability, net of current portion</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,020,227</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,032,066</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,519,364</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,602,294</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,051</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,792</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,784,975,303</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,740,954,074</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,710,837,583)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,622,965,136)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(623,461)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(662,601)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,540,310</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,349,129</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,059,674&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170,951,423&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inovio Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue from collaborative arrangements and other contracts</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">388,446&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,762&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">729,359&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,733,584</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,503,032</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62,734,891</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69,423,513</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,613,895</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,925,055</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,395,232</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,338,763</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of goodwill</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,513,371</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,513,371</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,347,479</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,941,458</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92,130,123</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117,275,647</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss from operations</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27,347,479)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(35,553,012)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(92,029,361)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(116,546,288)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,106,758</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,938,745</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,914,406</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,314,149</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(313,488)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(177,833)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(940,464)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investment in affiliated entity</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">324,251</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,374</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(136,061)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">987,758</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized gain (loss) on available-for-sale equity securities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,330,811</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(219,337)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,810,868</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,921,819</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(579,819)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,854</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,254,466)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,850,688)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25,165,478)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33,929,864)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(87,872,447)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(110,113,714)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.89)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.52)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.35)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.01)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average number of common shares used to compute net loss per share</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,140,497</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,385,229</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,216,983</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,986,840</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ino-20241114.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3171d0de-669c-4698-8a3a-dc1a7aa79716,g:5bb66b14-731b-41b6-9a0c-052f9423fe35-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://inovio.com/20241114" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://inovio.com/20241114">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20241114_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20241114_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://inovio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ino-20241114_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3171d0de-669c-4698-8a3a-dc1a7aa79716,g:5bb66b14-731b-41b6-9a0c-052f9423fe35-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f417f85f-debb-4adc-a289-8a6ef33d5120_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6e1ba88c-c874-4fd1-9f42-f38620d37c61_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_99010cda-4933-4d35-a457-c9ec1c735958_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b8312cc4-c13c-4b05-ae13-8d7ebe8380de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5a3adeef-4c3e-4abc-8155-505f487d8df3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_8ed14a14-e0b0-4e5b-aaca-0d744638267a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_41936dee-def9-411e-84d4-6ef49e91bf3b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ad2e2fb4-cb60-4c9d-bbdd-09ef1bde31b3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_0afab064-2296-4a04-aef7-5b1adc8d60d1_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b2b0aa17-52bf-4dda-8b62-e445796e0447_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d160e1f2-29c0-4dd7-97bd-24b0db89e87d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6c0124d7-5de9-4bb0-b5d1-585d6edc7194_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dce1670e-ee3a-483b-a56f-951fd2fc19ac_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4904c08b-8d4d-4cf6-83e3-543406aa7a0a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8f99379e-926b-4281-9aca-26c3489edfa6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b282b162-6620-4f8a-ad66-2e44347eb152_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_37b4018a-d8e6-453d-b46f-fd186f50c403_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d1923aa8-d502-4508-a791-02eeff1edf5f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c93113ef-508b-4e0b-97be-8709ecdb30a1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fd02a330-5bf0-44ff-b6f8-7fc7c7fac55d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_0013e496-19e0-48a4-b7c5-dadcbdd4fbc4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c8e7abef-e6cc-4aba-bb44-27d8f94dd29b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a63fd52b-7c92-403c-9d72-a23cea3ad81a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ino-20241114_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3171d0de-669c-4698-8a3a-dc1a7aa79716,g:5bb66b14-731b-41b6-9a0c-052f9423fe35-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://inovio.com/role/Cover" xlink:type="simple" xlink:href="ino-20241114.xsd#Cover"/>
  <link:presentationLink xlink:role="http://inovio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e8ed5788-1c99-495c-b0bc-e1f4a0314159" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_DocumentType_e8ed5788-1c99-495c-b0bc-e1f4a0314159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b3ae787f-ddc0-43c6-a327-145ee0c72519" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_DocumentPeriodEndDate_b3ae787f-ddc0-43c6-a327-145ee0c72519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_db4edf64-c36c-48a1-a6b9-ee8d40abfa11" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityRegistrantName_db4edf64-c36c-48a1-a6b9-ee8d40abfa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d33d214e-a51f-423e-b66e-3a84f5c9db9c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d33d214e-a51f-423e-b66e-3a84f5c9db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fb118aab-2618-482b-bc93-df40c77dfcae" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityFileNumber_fb118aab-2618-482b-bc93-df40c77dfcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a38b079d-9938-4fcf-aba1-01cb01fb86ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityTaxIdentificationNumber_a38b079d-9938-4fcf-aba1-01cb01fb86ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d29993c3-f313-491d-ab4d-54879bcfc441" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityAddressAddressLine1_d29993c3-f313-491d-ab4d-54879bcfc441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_590a47d6-5e9d-4a58-b17b-224898d9c495" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityAddressAddressLine2_590a47d6-5e9d-4a58-b17b-224898d9c495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f6dc392-4475-4b87-ab07-0cd944479124" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityAddressCityOrTown_8f6dc392-4475-4b87-ab07-0cd944479124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9d01634f-8d40-407f-8c42-215c1d5e69f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityAddressStateOrProvince_9d01634f-8d40-407f-8c42-215c1d5e69f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9826363a-4235-4435-81da-91139e0ae107" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityAddressPostalZipCode_9826363a-4235-4435-81da-91139e0ae107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_288391d3-e0c7-4502-9cc1-e1da6117ed67" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_CityAreaCode_288391d3-e0c7-4502-9cc1-e1da6117ed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2090c6b3-34fe-4c6d-a03a-6c943a61f927" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_LocalPhoneNumber_2090c6b3-34fe-4c6d-a03a-6c943a61f927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b8015c01-586b-4cc6-bd95-c3e6757046d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_WrittenCommunications_b8015c01-586b-4cc6-bd95-c3e6757046d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_923ace12-c6b6-4cd7-a973-548fcf4e9a04" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_SolicitingMaterial_923ace12-c6b6-4cd7-a973-548fcf4e9a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_84a0f837-f953-499e-909e-0e305aa8aa39" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_PreCommencementTenderOffer_84a0f837-f953-499e-909e-0e305aa8aa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_554c9c48-e622-436c-826b-d2f708695551" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_554c9c48-e622-436c-826b-d2f708695551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_64419bef-599a-45cc-86af-d4d265695b5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_Security12bTitle_64419bef-599a-45cc-86af-d4d265695b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_64ad1bd8-7605-42c8-8ea4-777cb7e3a7df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_TradingSymbol_64ad1bd8-7605-42c8-8ea4-777cb7e3a7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4a8ad964-b16f-4337-9ac0-85130ac48d51" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_SecurityExchangeName_4a8ad964-b16f-4337-9ac0-85130ac48d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ba993f27-582c-4491-b0d1-a0993c279a58" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityEmergingGrowthCompany_ba993f27-582c-4491-b0d1-a0993c279a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_eb14049e-5b53-4a9b-ac51-1c50777b5375" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_EntityCentralIndexKey_eb14049e-5b53-4a9b-ac51-1c50777b5375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5cbce901-4bc2-4f60-82fb-9a7eabce4dc3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8088b75-723f-4a5a-bb11-2a31facc0cdc" xlink:to="loc_dei_AmendmentFlag_5cbce901-4bc2-4f60-82fb-9a7eabce4dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>picture3.jpg
<TEXT>
begin 644 picture3.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #@ K8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBDH 6BDI: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFO(
ML:,[L$11DLQP /6@!U%9B^*-&D9575K%F8X %RA)_6M.@ HHHH **I7FMZ=I
MTHBN[^UM92-P2:94./7!--M=>TR^G$-MJ-I<3,"1'%.K,0.IP#0!?HI*6@ H
MHHH **** "BBB@ HHHH ***@O+ZWT^'SKJXBMHLX\R9PBY/09- $]%4;37=-
MU"80VNH6MS+C/EPSJ[8'4X!J]0 4444 %%)1F@!:*3-&X>M "TU^U!85R'Q%
M^(^E_#O25N[]O-GD.(;6(@R2GV]!ZDUG4J1IP<YNR1$YQA%RD[(ZUFV]\4#G
MFOG?PK\6O'OQ/UZ>U\/IIFF00H&E^U(9"BDD!NH)/'05K^+_ !K\1/A?9QZG
MK+Z-K>GR,(2+='@*2'IUR2.#7FQS"E4I^V2?+WL<D<7"4/:).W<]RXI5KS3X
M;?&?1?'[?9$9['4MNXVLY&2.F4/1O7'7FO2(N,UW4:U.O'GINYT4ZL:L>:+)
M:*3(HW#UKH-A:*3(]:6@ HHJM?:G9Z:J->7<%HKG"F>14!/H,F@"S15&SUS3
M=0F\JUU"UN9<;O+AF5VP.IP#5Z@ HHHH **** "BBB@ HHHH **** "BBH;J
M\@L83-<SQV\0X,DKA5'XF@":BLV'Q)I%Q*D46JV4DDAVHB7"$L?0#/)K2H *
M*ANKR"QA,US/';PKUDE<*H_$U4@\1:3=3)%#J=G+*YPL<=PC,Q]  >: -&BB
MB@ HHHH ***2@!:*3-0WE[;Z?"9KJ>.VA'!DE<(N3[F@">BO+/$W[2OPX\+?
M:%NO%%K<3P/LDM[+,\@.<=%%<+KG[<7@33TC_LVTU;6&;[P6#R-OXN1F@#Z-
MHKY:_P"&]_#8_P"95UC_ +^P_P#Q56=-_;M\(W-Y%'>:'K%A Q^:<^7)M_X"
MIR: /IRBO&-$_:W^&.N7+PG7FTW"[O,U&V>!#]&(KTW0?%6C^*K6.YTC5+34
MX73>IMIE?*^N <X^M &U124M !1110 4444 %%%% !1110 4444 %%%% !11
M10 5@^/>? OB('_H&W/_ **:MZL+QY_R(WB+_L'7'_HIJ /RN\%V\7_"2>'_
M -VG_'[;?PC_ )Z+7ZUQ_P"K7Z"OR8\%_P#(R>'_ /K]MO\ T8M?K/'_ *M?
MH* 'T444 ?!7[=44<GQBTXNBM_Q)H>6 _P">LU>"^']6OO"NM6FKZ1.]AJ5K
M()8;B+Y2#[GN".".G->^?MT?\E@T[K_R!H>AQ_RUFKSC0/@WJGBKX4ZAXRTA
M6OGTV\:&[LHT^80A0WFH.^.XZXY[4 ?=WP/^,VF?&+PO%>VK+;ZK;A8]1L&X
M:&3'4#NC=5/]:]+R/6ORS^%?Q.U3X3^+K77=)VS!1Y=S;-PEQ"3RI]#W!'?%
M?I1X"\::;\0O"^GZ_I$IEL;M-PW$;HVZ%&'8@\4 =+129I: "BBB@ HHHH *
M*** "O _VVE5_@7<!@&']H6O!'^W7OE>"?ML?\D+N/\ L(6O_H= 'SC^Q3$B
M?'>V*HJG^S;KD#_<K]":_/G]BO\ Y+M;?]@VZ_\ 9*_0:@ IK4ZD:@!AIDS*
MD)8L$5>2S'@#U-+)D+TSS7SQ\8OB)#K'CBT\(W&H-I^@1RQ_VG-'D>9D@["P
MZ)C&?<G/2N/$XF.&BI3W9S5JT:$5*74ZSQ?^T-HGAN2:.QMKG7'AD,<LUNN(
M$?ICS#P>>,"N)/[4FM*J7$WAB%+%C_KA(^,9[,1M_7K7M=YX-T?4/",VAQ6L
M":;<0>4JP *H!'RLI'X$'VKQ[X,ZDWA3Q'J/P\\1Q),HE:2T\Y,H3C)QN[,,
M$>^17BXF6+C6BO:\L9=EU['G5GB/:1_>63\NIU?A?]H[POKJF*\\[2;CDA+C
M#*PQD?..,GTKROPKIMQ\=OBM>7VHL[:5;GS2FXX6('$<8ST#8R>_-=;^T%\-
M_#6B>&VUJPLEL-0:9%'D-M63<WS$KT) KSKX4_$VY^%]]BZL6ETO4-LK87$F
M!QO0_P 0]J\K$XBK[>&'Q;]U:Z=?4XZU6?MHT<0[I=OU/1OA-);Z'\=O%^D1
MPB.*8,L048"!"#CZ?-6G^U7J"P>#M.LV_P!9<7.\8_V%.?\ T(?G6!X0U'39
M_P!HQ]1T^Z6XL]2LVG1QW9U4D>WW>E:O[3$EM>ZIX.L)G7Y[LF52<8C8JI)]
MNM=G-!8"I"#T3:^]F]X_59Q3TO\ J9'Q:^$K:3IEMXP\.9LYK>*.6YBB^4KA
M1^\3'0CN/QK?\._M*Z3!X/MKC5P\FN*#&]K:Q_ZPCHP)X 8?J".U9?Q6^/%M
M:V,WA[PV4NF:+R);T#=''D;2J#^)L?A7E_PK\.V&I?$*QTG7[24QR[@D,A*#
M>!N&_P!B >/<5P3Q7L,2H8'KH^USEE75&ORX?KOVN>L6/[0WB;Q-?.OA[P=]
MLMNH:21L@9P26 V]?2M3P7\>[[Q!)J(O/#[R0Z><W%SI;F=(UY^;:<%NF>.W
M-6/CCXNA\#^%8/#^BPQP7^IYACBMU \N/HQ '0G.T>Y)[5TOPA\ +X#\(P6T
MHS?W!$UTPY^<@87/HH 'X$]Z]JE]9>(]FJE[;Z*R[)'HP]M[7EY[VW.OT75K
M/6K%+RPN([JWDZ/&<CZ>Q]C6BO>OG?Q#\0-.^&_QA<:9=M-IM[A=7LH5S'',
M>!(O^UTW >GJ:^@[2020AP00PR"#D'WKUL/B8UW**>L79G?2K1J-QOJMR>O&
M?VK/ADOQ)^%=YY-NLVJ:3F_M,C).T?.@]-RY_*O9JBF7>NTKN5@05(R#7<=)
M^4_PW\72_#SQKHWB.S7#64RNX4<O&>'3CKE<\'OCTK]3M$U6VUS2;74+259K
M6ZB6:*13D,K $<_C7YM?M!?#S_A6?Q4U?3(8V33[A_MMF6R1Y<AR5R>NTD@^
MG%?4/[%/Q$/B3P%/X9NI-U[H+@0Y)):V<DI^"G<N/0#UH ^DZ*:N=O/6G4 %
M%%% !1110 4444 %%%% "5\;_MV?$475YI7@>UD5DB'V^^4<_.01$A]" 6;!
M_O*:^M/$6LVWAO2;_5KYC'96-N]Q,PY.U02<#N>,8K\M/''BZ\\>>+M5\0WW
M-QJ%P9=FXD(I.$0$] %P!]* /7_V-/AC#XN^)C:Y<6R/I^@(LZDH"#<L2(OQ
M&&?([H*^_P"/_5K]*\I_9O\ AN?AG\*M+L[B(KJM\/MU[D8(DD PI_W5"@CU
M!/>O5USM&>M 'BW[8BA_@+K@8!AYMOP1_P!-5KXL_9ZAC7XX^"2(U!_M).0!
M_=:OM3]L+_D@VM_]=;?_ -&K7Q=^SW_R7#P3_P!A)/\ T%J /TZHHHH ***3
M- !63K_B#3?"NFW&HZK>P:?8Q M)<7+A5'!/YX'0<USOQ4^*6B_"3PW)K&M3
M'YF*6UG&1YMU)V51_,] *_//XJ?&+Q%\6]6:]UR[VV4;E[73HSB"VSQT[G'&
M3R: /H'XG_MQ.SR67@33@%#;?[5U&,G/3[D6?]X?-]17S3XB\;>*/B)?;=6U
M?4==N9<;8&=G# =,1J,''^[7L?P9_9 U[QU'#JGB8S>'-%8@I R_Z5.I7((!
MX09QRW/7I7V#X$^$OA3X:VJP>'M%@M).K73KOG<CC+.>>] 'P=X5_9=^(_BR
M'S;;PZVG0;5=)-3E6 .K#@J.2>/85Z19_L&>)Y(87N?$VEVSMAI(EAD<H>X#
M=#7V\.@I: /DBW_8#LOLX\_QC=";N([1-GZG-8>H?L#ZRMP1I_BRQ-OV^TVK
M[O\ QTXK[3HH _/7Q-^QO\1O#_VF2TM+/6[>$95K.<+))SU6-N?PS7E-]I/B
M/X=ZLRW-MJ7AO44;8S$/;N3P<!APPZ< D<5^L%96N>'--\2:>]EJMA;ZC:2*
M5:&YC#C!&#UZ<>E 'PS\.?VS/&'A5XK?Q$J^*-.!RTDN$NE!.20XX8]@"!7U
M[\,?C%X7^+&GF?0+]9;F,*T]C-\D\.<]5[C(/(XKPOXM_L2V-_YVH> Y_P"S
M[HG<=)NFS Q).=CGE, C@Y''O7RBR^(?AOXI <7N@:]82 CK'(C*W'L5X]P<
M4 ?J_FEKYX_9[_:AM?BA-#H/B#R=/\4;?W3+\L5Z ,G;_=?&3M[]J^ALB@!:
M*** "BBB@ HHHH **** "BBB@ HHHH *PO'G_(C>(O\ L'7'_HIJW:PO'G_(
MC>(O^P=<?^BFH _++P7_ ,C)X?\ ^OVV_P#1BU^L\?\ JU^@K\F/!?\ R,GA
M_P#Z_;;_ -&+7ZSQ_P"K7Z"@!]%%% 'P9^W1_P EAT[_ + T/_HV:O6OV$@&
M^&>N C(.I,"#_N+7DO[='_)8=._[ T/_ *-FKUO]A'_DFNM_]A-O_0%H \<_
M:H_9_/PTU5_$NBH7\-:A,?,AQS9S-_#_ +C'IZ'CTKF_V<_CE<?![Q6L=Y/(
M_A>^?;>P ;O*/03*.Q'?'45^A.O:#8^)M)N],U6TCO;"ZC,4\$@RKJ?ZCK7Y
MQ?';X-WOP;\826FR6;0[IB^G7L@R)$Z[&;^^O<=QS0!^DFE:A;:O9V]_9W$=
MU:W""2&:%MRNA&00:O9'K7P]^R3^T(WA6\M_!&O29T:ZDVZ?=N<?992?]6W^
MP3T/8_6OMR/[PSU_SQ0!-1110 4444 %%%% !7@G[;'_ "0NX_["%K_Z'7O=
M>"?ML?\ )"[C_L(6O_H= 'SI^Q7_ ,EVMO\ L&W7_LE?H-7Y\_L5_P#)=K;_
M +!MU_[)7Z#4 %-=MHI=P]:@O+B*VMWFFE2**,%WD=@JJHY))["C?03=E=BL
MW4CI7RCX.\(V'Q*\=>-K*[!2XD,TUK*3DQ,)NOZ@?3->@>-/VQ?A?X)N9;>3
M7_[6N8F,<EOI41G8<=<\*1[@FOG+P;^U5X0\)_%74->4:F='O))]ZK9CS/+9
MBR@+NXPVW\JY\;D6.QLJ4HT9.-^Q\MC\RP7/",ZBWUU/>_A'\0+KP'K#>!?%
M@-J\3[+.YE/RX)X7)_A/\)_"M3]H;P7,UI;>,=,/EZCI15I&48)C!R'S_L')
M^A->/_%/]J#X1_$C0S_I&I0:M ,VL[6/.3_"WS?=/Z=16;X9_;;5O!O_  C-
MAX;U+Q9XE=3#:0^3D21[2 7 R3MXSZCG(H609C[-X>K3?+TD^AE_:>$<7A^>
M_9HZKXF?$2;XMQ^%=)TZ'==L%,\(7I<M\H /L,MCW%>[77P@T/5O!6G^'KZV
M\Q;&%4BN$)\Q&QRRM]2:X/\ 9W^!M]X3@3Q-XN$4OBBX4F*R@_U&F1L.47^]
M(>[?@..OO42E>H.?>N"EEW)*3Q#4I/3Y(]?!T95(NK77O2_(^;_^&>?$WA#7
M+?5?#6HVMY-;S;XTN@8SMQ@[CR#WZ"F>)/@W\1/B!K%O<Z_+ID"QH85DA?.Q
M"2<8 R>:^ECGM30IK+^R,/R\JOR]C7ZA1Y>76WX'DOP[_9\TCP;/%?WS?VOJ
MB<JSKB*,^JKZ\=3ZUYK\>=-E\&_%+3?$:(98KAHIUW8 +Q$ H/; 4D^]?4N>
M<8.:YGXA>!+/X@>'I=.NQY4GWX+A5!:)QT8?R_&IQ66P>&=/#KE:U0J^#BZ7
M)25FM5ZGC'PITJZ^+'Q%O?&FJQL;"SD"VD; 8W#E5_X #D^Y!KL/C1\6CX3M
M1H6D,TWB&\ 15AY: -QG']X] .O?Z^<77Q0\0?L_V,?A#4O#\:Q,LIM-?6<)
M;LS$D AAR^2>,YP#Z<^;?#O]I'X;^"_$%[K'B6;5]9\0^:P$T-H)HT/=E8MR
MQ]>PX%5A,OQE>"H8:#E.2NY+H>/+'4L,O8SERR?Q-G6_$'X7OX'^'^EWNH#?
MKFH7F;AF;)C!1CLSZYP2?7Z5](_";6#KOP\T*\9?+9K94*YS]S*9S[[:^7OB
MA\=M#^-=CIUUX=.H1Z?9F42+?0>5F3 P5&3G W?G79?#?]M+X4V^C:;HLE]=
MZ/\ 9;9$:>\M&2$L -VTJ6)R<]N]5EV65XXVM&C!V@DGZ^88;&X2CB)*-1*-
MEOU/I_<#WS3EK'\-^)M)\5:7%J&D:E;ZE92\I/;RAU/&<9!X/J#R*V%KVFG%
MV>A]5&2FN:+NCYS_ &U_AJ/$W@&'Q/:Q@ZAH3;I2!R]LYPX]3M." />OE7X!
M_$5OAC\3])U9Y/+TZ5OLE\&/'DR$ L?3:=K9] 1WK]*]7TVWUC3KJQND$EK=
M1-#*A.-R,"",_0U^6OQ&\$W'P]\<:SX=NQEK.=EC=E($D1Y1AR3@J1^5!1^J
M5NP>/>K;E;D-ZC%2UXW^RK\23\0OA39+=3>;JFDG[#=%CEFV@;)#D\[D*DGI
MG([5[)0 4444 %%%% !1110 4F<=>*6J]U(L*M)(XBB4%G=F "@#DD]OK0!\
MU_MP?$8:'X/M/"-K+B[UIA+<;3RENAR 1_M.!@C^X?6OG/\ 9M^&Y^)?Q6TV
MVEBW:98G[?>97(:-",(<\$,VT$=<%O2L;XW?$*3XG?$S6=;#LUGYGV>R5LC;
M GRIQDX)QDXXR37U]^QQ\.6\'_#+^VKF'9J'B!A=99?F$ !$0/)!R"7'^_[4
M ?0$2[8P.M/IJ_=%.H \6_;"_P"2#:W_ -=;?_T:M?%W[/?_ "7#P3_V$D_]
M!:OM']L+_D@VM_\ 76W_ /1JU\7?L]_\EP\$_P#823_T%J /TZHHHH *YKQY
MXTTWX?>&=0U[5YU@L[1"_)P9&Q\J+ZLQX'Y]JZ3/;O7P9^V/\7'\8>-F\)V,
MQ.C:+)B8*>)KK^(GC^ ?*/?)[T >3?%#XF:U\7/%DVM:L[,Y/EVEG'DI;1Y^
M6-!ZGN>I-?5G[-_[+-KX;L[7Q-XPLUNM;D EM=/E&Z.S'9F'1I#Q[#I7"?L=
M? Z+Q-?'QQKMJLVG6<GEZ;"YRLDP/S2D=PG09_BS_=K[;7.T9ZT "_=%+110
M 4444 %%%% !1110 5YA\;/@AI'QGT#[-=*MEK-N"UEJ:)EHF/\ "W]Y#W';
MJ.17I]% 'Y0^*?"VN?#7Q9/I.J12:9K%A(&5HVQGG*RHW\0.,@CW[C%?>'[,
MOQRB^+7ADV5^WE^)M+11>;N/M"]!,OUX!'8_6I/VF/@HOQ9\&M/8Q!?$FEH\
MUFZJ,S+_ !0$^C8R/0X]Z^%/AWXXU+X7>-M/UZR#1SV<FV>W<,OF1YQ)&PZ]
M,C'J* /U4W#UI:R/#NMV?BC0]/U?3W6:SO85GAD4C[K#.#@]1T/N#6O0 444
M4 %%%% !1110 4444 %%%% !6%X\_P"1&\1?]@ZX_P#135NUA>//^1&\1?\
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MVTDN[/@\[KQKXF&"J-\BU=MWV1K_ !8_8U\6_"!8?$W@+5KW5Q:!2ZVN8[Z
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M&K7Q=^SW_P EP\$_]A)/_06K[1_;"_Y(-K?_ %UM_P#T:M?%W[/?_)</!/\
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M&/[P&/2O>_M"IAZDL*I\L):P:T2[7\N_F?._4(8BC'%.+E.%U-/KW_X!\O\
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MIW_8&A_]&S5ZY^P?_P DUUO_ +";?^@+7D'[=4T:_&'3MTBK_P 2:'[S ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45800314599632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 14,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Inovio Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M%>CJPUOX86!46KSY+I2!]^CB=,T9V(.] ;Y?*F7>!_9ENOPO9/PW4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ^X!N69E<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #[@&Y9" EF"%X$   7$0  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ^X!N69^@&_"Q @  X@P   T
M             ( !H@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #[@&Y9
MEXJ[',     3 @  "P              @ %^#P  7W)E;',O+G)E;'-02P$"
M% ,4    " #[@&Y9JL0B%C,!   B @  #P              @ %G$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ ^X!N620>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ ^X!N6660>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ino-20241114.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inovio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ino-20241114.htm">ino-20241114.htm</File>
    <File>ino-20241114.xsd</File>
    <File>ino-20241114_lab.xml</File>
    <File>ino-20241114_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ino-20241114.htm": {
   "nsprefix": "ino",
   "nsuri": "http://inovio.com/20241114",
   "dts": {
    "inline": {
     "local": [
      "ino-20241114.htm"
     ]
    },
    "schema": {
     "local": [
      "ino-20241114.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20241114_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20241114_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://inovio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241114.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241114.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001055726-24-000053-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-24-000053-xbrl.zip
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MQF  K=O>Y%VWJ! :AV>G[\XF^^ADY@-W&'2&E"SF?P$7*'&9L%PN)P+PTPO
M-1VWHM5G2QF.16DHIFJYG*97BI5"Q7Q0'-Z W=VM#'ZB3">6LSPY8(+\%0CN
MVUP5N]0:-*09?-[4GKX5M5C&_R?0BAU9VO"&0^[[,0?1ZI%0T!/F[8?32Y8
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M*898,E!A&_D]H_*?^"1/6M&>N]./,F&RIL@YM0V*3&O))R!Z9<C9.4I#7W]
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M3^9L>#[VR&&)%2S!^HMPD_U^T7ES<IPQ]*/C)*G6T+TDM.EI-,FT$FA*I-W
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M[G&W>9=$F]_&N3TZ?;5^)5O^V]C35_\#4$L#!!0    ( /N ;EGR408XT08
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MZ'W4V;"P?VVQ7^A'7-0<).&>P_]K*IHF5&?U:G5=/6Z>-W.K"*Y<A()0TN(
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M9L_$N\"&DX/'"^U+^[\1)P?_ U!+ P04    " #[@&Y9J%*QN+,E  #/@ $
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M_3<=UW%>YSM_IBW0BJ]4!A01W+NIUW/0<CR$#;Y*C4:3&/8TF+)09(+U=<(
MOS7/:;19.ADCBE&FC1,]UBF(N)$,AB)6Z8CI/A-!IG0,'\H4"3)D @XJ@2\
M\XG!=J#CODQD',#9UD,E":E=0J7;VF54^O4F0N<M8B\=ZAO$0D]%*ILBA@I<
M9IH!.">!!%:$_V5J(.-:.I:!ZJN !=-,9_H+_'3) ADA]M*QCE-X>B!4G&;L
MUT__KK6(C?$GQZ$?PT1=2\1T,E$9:4)XI5DAA=?!.X5*;L2492I-)]*(@;$8
MJR@"N%3D\'7(H: !0P ADU_&L 'D7$!7#-L*(AT#R^:8RX; QRKNJRA+P*Y9
MA<1 )X9$0G:CLB'0 "R=V27323* P\&C*$X^?_X$.,\4X"YEN@?'OH8]J)A]
M&@H@,.?[;_SV:^:R+ &%46F";6B"-_ =%4\ +2#G!PDJ9R/6QR)!Z9_(P202
MF4ZF@-O>".@ ,)W.*8N*F9^/F4]!(,<ZKH7R6H$ __G]*1OI<!))0A/P:'!%
MN CT:!Q)XL+>E$G@36!&,L@J[#P?=A =,ZX 7AFAQF09^ L2;2+$S$B%-4!$
M<R/QMAVX?WK_?[]]_./R5_;;V=GE^8=?./MTRJP<8Q_TM1SUP,QW?&XH*__$
M.@4G'TXOWI[^_OTWS0[][25G@O64SL!LM'8F4JF(IP"78((6)< ,"%M&>HRB
MQBB7T4@FZ#^H_^#?WGX @I>A"M!O0$MF**,QT#TXW<:B2'#]C(VE!OIG_42/
MR$I)9$1N>:A2":HFY2P MT0FG+X%"DZBRIJDI0<R'8*F$W&L)S&J2@4ZJU]X
M,XGU9A"EV5#"_]'U^=NZ/CFSV2U=JQ!ML9A-QB%J4:(-:Q,;"-ACH^&4UO>
M-(@E&Z__E&C5D\) 9/1D&94BO$9@ =8*LX,L11F!J4C*1) L0QL!G6>FQR2P
M8*&RH5!GE_I& ' !Q"D;:!%Q=B/1<D%$(PD(L#S%O&#,A2*B1T\2$I16)L+F
M0"1.I4A0+L):0P64 D8(:#A814:X>OE4"K]&)BTB>AP)VB(0@(ZNI?E; F\%
MZHG*] (PGO0%AA+PJ&0P&0,)OX'1H4C6)FA6)XDPK*!C:S?C$^8@=?:G^0H<
M/5?(?'&#1KZ8=6?2!];)3PZ'R\4.)\P!EZ9"A>QM4F?_$L'?$XDH9A=#*;CE
M7^+F]NN4?8)W*M0!A+TW0R7[[.R+#"896OP?^^ T2%C&4L1'>&6)F.<<#SB#
M]2,-#@0;)/H&H8/A+7P4O4>1!$-C=P(Q1\B7L-J4C;5"JQ&.FZ]7[' ,/ _0
M  HR- @( IS!:X3!62+&$G8;Y 2&1('T,F>.@F$#1!:1P6,P0.ZK=9[@=Y7D
MP@&0(BT#X\8*ES=>X44/\\@&'A-7O=LCPR7&>HPF%ME5)2>*0 (:'J!!2!\N
M6./S'M5*TSP +!.G]60L^RK#@U@H$@NENG0:))[^!,"4BK[,IK2@1&R+P)R-
M Z)'L$GT#,SI8(/%F6Y$2EY';)%R@[YDIB.9D"#&U8AQ%_>$Q(IG*[L$UB.H
MLU-0N@@8P-Z4(PGAD]:Z08XFUD"7-E!C<E<,-^+NP*\9U$ VCV9O#"=)C@T\
M#Z%U7IQ%"FA@=B;8DN'W>8(#WBWD0%\"R 'R0XUB*-<.O42+4(+O'$](9\)V
MR\3'08V)*!L&(I&YODAR%WFJ$WA ]9D8XT<RK%L6WBDUL2H^: S($."3$#F_
MFH MF>!3+WYZH@C@=L*>[Z4 20CH4:C.^8Q <A,(3C<!.H"=?0;^4XEQF#[E
MS)GI5.W6.5=K^05-,$[42"367$-ICD$?XOQ<0<NR?VCH%9ADT9 3>70 3:H(
M80D/8M  C;)%F-;S8''ACZHXB"8A1A\* \/XIU9F(M.1'LP*H0M*D*\VPXT!
M6)(3^'@?%(]13"B/23;L/+;N8C9\P?E,,6%$Z)F=J7N,1^L2H)M0BA@7PGU)
MBRXJFOO4Z%)4<R&6F3X@F)D--2BDM4.:RS(>#$VP; (]B<*9!@$#(@5:8T"2
MH&U&X%^ VIHM NP$)E(V!"-X"' RT+B1I"9*D7:$R"GP%ZBUF)VFJ09&*TR=
M-^3IH"0RMM7)Z>F;SR_9!<(&8/VF",L;5C"K>:UGH9 6.LIK>-<@((F(R6\#
M9+S.]/A5S:NO2+;UP$XP9)X-MTG5[!P3<;&P)%P(^VN5@+2<0;D.#P*I8IPA
M R.&3/M<S-@X+3'( <8_GS^(LW'(YCPN1:N7I$0A/X#9%R4%MXH()=(L:?+F
M;>=_<B&1LSSQ:YH!.>1<BUQV(^45:[JX3 CDG)F0!P,K4?0BE0YSN3,"V0?:
M--]4A?JG0OU9.?<QE_>8<\$P,@ O'0\IE]F+M [+J%=E EK*H,RM5/+@(I#;
M,P4"0GHF\HTVN17-Y?J-93&Y6-&1?\O6*C1F7Q&]5$>3;/DK]Q2!F'\/DQG9
M#62METAQ51-]$("O1 1'2E\\4^%)1>6/$7 J[D=B-#+V^4S,4?"K'#B8,VQ*
MU+Y:,>U'!N'YDV\;IMK(7@"C0,><%,@5AN#(5QJ"R*??4C!PP$Z(!Q7,GP;F
MIZ$84]S2A/W)VB9G0QIQ7:2Z%6*%@F9R-!X*\-<QI&T5>Z6#GTHZO2D,)R)U
MK+M+K:"R)0=AR>6:22D*"RY(*1,X0YT<J@1S Q+C:.C7T()8F4F9"2I**A1T
M&>,F'9,8W0RF6HT22Z8>L\+XTV!\%=@!LPNN-%ED-DQK0]@8$<T]WU"CITSA
M=S2Y[)K6\BJ;7+'.6"@Q)0A&-7Y58416EV(&%8:?G*=SQ&%-X#4&:1 +"C@K
ML(D?$][!7! &]% <S\R/D0H2+6/PFG6\$B\[%7AS&W<&WMYA_N1BEC\YR_,G
M6PS!4>'T+2$XRG'?E?-AJ<R*K,:*% VRLG%Z'YT(JK./)@_GN;,LG4T.T;LX
M<UNE\!ILJN-\QRDQG"A).5B,'!JYGW]SEH ITLX*[;!K#,=9=P^?H_PP.30S
M$0$GD_,ZHGBR)P$H<O;H/?$Z<,=,'GAG:EJ(*N8C6!<Z4-*$6/\M E-Q,0MC
M;9-ZB6AV#WSOT*SX-R7^=@-.]>5JKYV2GB;)-,?2^&-NH2U8 ,!.)Q\Q<HT2
MA5B=[',0 KH0%#).- 57"HE1B -3</($\F!6S1*"%:+25<:CR0:CL6'2TK-X
MD=OYCIUT269Z[DL3$TKDWQ.%WXSUZFVP$U67=5Z4L!00(;&', E-F8DNA!:6
MD&AJ0KH!4T7?U-F[28+%$)SY/FS!\8L]P.$+< T%2DTX1Z;F /_I\TO.1@"Y
M29(7;\P5^L(I(O@T8\T&(*8WP5]3"GG%#.,\?#7 36WP2KDZ Q\)TX(JBCU1
M0?+)Q\^?YT]P\N;S_WRR5(+G-9*Y[<*972\_,R@7_(Q=2:O7;'E)216:+*-1
ME%4L_JN$JAYK,E11DJ>)DO@."@AOI8!(I"W@$C-KIRBO/ V!28$USU!NL9/3
MLY<52IX&)1_T*G"?I6Q #:>)D;2_)"*4S)V5KI'IF:.LPL73X.(W#7JNCTJ;
MBD)7H*4HF2FXA1"AXK^DT9BIHC0_Z,03S_GN)8FT/K#88 (JK?O=FFQ3*97[
ME<IO.E1]!1AX*Y,K,:U]2N %5],9BZ3@N&,.9&2JZTS->%Y4D!LCML:PZ=8H
M;;NZ06FG<63=_FWB"(,E=RO^O"V-*C,C$Y.?1&!YEPIW !,#4/?SL>';RGEV
MRO]974QH#-%/:FP([@]J$3C$/N@=% XV )87_9J</%45FD)_4TPH;*3+LS$N
M$ 1?YR"W-MT#MSCN5HN=P$(7Y3KH(D:& "MWW.A$CX<BF<8#"<^E?T_$"/ML
M3,!>)."64](9:\^O8C3YR6U+M,B*%AW\=3(8,AT/-%7;Z!C-3!OBMTVGMNRT
M<-C/)O!B"3;1'S$\ABZD2O,895JJ$0^MCP&+HCMK^E$_@-(>YA5U)G)+R]6Q
M&\*V>IA8Q;NWI^0SVR(>M(NQ*LV$"_-NCZ)EWKP_E)CL*JJ#X,"V8\*\'';R
MUR0V=@(M(>SWTDR:OADLIE49_+9966HE)IY!3&#(?%E4N+LC*GRWX6Q?5 PE
M."E8T8O,W]-H05O3"CDH4H&,D4'.>CH2[-J$FSD[2ZYE3W__C=/V7]<9MO[)
MS'13@=DVE-CC%<[8#%>RW-_7&.Q:ZL>#5X8J#29I.L^7\T@S_%GQUE?AK4]Y
M8&&AD3 DQ%AT_O+S;[5&P['X(81OFZV:_G;9"OLBR [&3DM04.>Q!L5DXF*6
MQE%0#:DQUO1BC %Z&?:8?<'=RC&[H5IT[)@CZ-O0^1PS[%;CPVITK#5VJ.+F
M)V[N6IW[%^F0,_PW._M[HJY%1+R-!'HQ!*/*=."=@_V6DKF8;I.%3&S_E*I-
M+N0X,_WL7L/TLV.+.!X&_\WDPF'2V6'4[# FRO-MQZ]W&.PW6LP*?>OXS;I7
M?"3HS6]E8%_LT(N]#;-V%:T^D%:+AAA$Z-M2S_+)Y^^_\3JOW[YD9U_&:)>D
M\UF@;<#0;HG2F10'F0T>2"3VN\?9,,4P%5#:*EHVE.ETZNU;*+-9;Q:?Y&NG
M8B2I^%V3)C;$B;FXO)H._[JT,W1H3*L@@,$V!:(,IHYTF\3#MFC87YA,!@N-
M\@&8AH;'[#,R'@ TC.,#2JPOJ;W=MA7J28;-Z0Q'"2D<+):[G6CIF5$ I6YT
M#EOH8P5+;\HB?8.+C\:1GDI;=PON).Q3V+D,<!I;!SK+WN*( 1((:::#JUJ/
M*@KG'P;_%A.Q%-6Y!AB@EY!6//UU>/H7B@P:VC@MI>?!*#KYA0CU=(&KM^H:
MV2V5>,<HD'IKB1?7XO-YGN[6N^NS=+DP(M]6U82R9A/*EICP%I%;DH'S!2^%
MM+M7O-TF%^\0>_%BN5TD!\")^1XKP;A5P7B)#:?LXUC:'NK=L6S,SG2QLP59
MZ+9+%O.&1L^<-/2:ZXK#M\826?=%GHD$YZ.<$AGH00P ".U\(V*H@=;A#7:
M8AVT2LRLZ"%.)$"SZ%NG,3._JL#35^&(#V 'OM?I#E@!N),(=K*AKD>A_ZW;
MK+LYX5 QX+>->J>+)(TY;!68>08*E2QZK< -\VP1Y^]&*O2\&8N8Q9QZT[U[
ML4WV7+FV7XFV+Q W*?L(WE&&(U46.C>W0N6WQUEL>@73:&ZK[I0=U!'6RIC#
MZ-EAX(NEQ[!1JS\ABKO!86HT7+;\,%*M6S:&;UV8QM91!\2TH'.D?+1>J*QV
M8 ;>R'[?#I^CXI O.-D&BW$Q$E2\TJ8IC7648@@V4@&6-?!\]DWYS2M.P>W
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MCB?4^K68SO_?@C?S^_]H,,A" XZ1F+\790'+ZVQ2%E#:K\)1WB3S1N+*QIK
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M]O<X(5,1U!,0E!55"YZ-TR2 [&KM[[9GUE6;W-XF#S[+]EE>RWABKP EQPR
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M/U!+ 0(4 Q0    ( /N ;EDL%^&JUP\   N1   0              "  0
M  !I;F\M,C R-#$Q,30N:'1M4$L! A0#%     @ ^X!N65:TK(!? @  Y 8
M !               ( !!1   &EN;RTR,#(T,3$Q-"YX<V102P$"% ,4
M" #[@&Y9ZG9?%E4*   &6   %               @ &2$@  :6YO+3(P,C0Q
M,3$T7VQA8BYX;6Q02P$"% ,4    " #[@&Y9\E$&.-$&  #K,@  %
M        @ $9'0  :6YO+3(P,C0Q,3$T7W!R92YX;6Q02P$"% ,4    " #[
M@&Y9J%*QN+,E  #/@ $ %0              @ $<)   :6YO+3DS,#(T>#AK
?97@Y.3$N:'1M4$L%!@     %  4 0P$   )*      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ino-20241114_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20241114.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-11-14</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001055726</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Inovio Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-14888</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">440-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
